Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.

Abstract

We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, -0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.

• Authors: Bonnie P Hersh, Nancy L Earl, Robert A Hauser, Mark Stacy
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 25 Issue 7 Pg. 927-31 (May 15 2010) ISSN: 1531-8257 [Electronic] United States
• PMID: 20461810 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: (c) 2010 Movement Disorder Society.

Chemical References

• Delayed-Action Preparations
• Dopamine Agonists
• Indoles
• ropinirole

Topics

• Aged
• Delayed-Action Preparations
• Dopamine Agonists (therapeutic use)
• Double-Blind Method
• Female
• Humans
• Indoles (therapeutic use)
• Male
• Movement Disorders (diagnosis, epidemiology)
• Parkinson Disease (drug therapy, epidemiology)
• Severity of Illness Index
• Treatment Outcome